Search
for
Sort by
Research 91–120 of 1000+
- Bladder Cancer: The Hormonal Dependence Enigma and a New Hormonal Player
- Efficacy of interventions for prevention of chemotherapy‐induced alopecia: A systematic review and meta‐analysis
- Breast implant illness: a topic in review
- DRUG NEWS
- Gender-Affirming Hormone Therapy for Transgender Females
- Breast Implant-Associated Immunological Disorders
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Trichology to predict efficacy of scalp cooling: New pathologic insights besides encouraging clinical results.
- Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia
- LOP14
- LOP14
- Climacteric Commentaries
- Skin diseases associated with Agent Orange and other organochlorine exposures.
- Abstract SS02-02: Chemoprevention: Poised for Success
- Trailing the Path to Preventive Oncology
- Ginseng phytochemicals as therapeutics in oncology: Recent perspectives
- Testosterone therapy in women: Myths and misconceptions
- Clinical perspective on management of key adverse events with sacituzumab govitecan
- Primary Chemoprevention Still Lacks Favor with General Physicians & Patients
- Testosterone therapy for transgender men
- Controversies in Polycystic Ovary Syndrome
- Estrogens and aging skin
- Permanent chemotherapy-induced alopecia: Case report and review of the literature
- Sacituzumab Govitecan-Hziy (Trodelvy™)
- Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.
- Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies
- Connexin 26 (<i>GJB2</i>) mutations in keratitis–ichthyosis–deafness syndrome presenting with squamous cell carcinoma
- Putting it all together: How do primary care physicians interpret and use the results of prevention trials?
- Chemoprevention – History and general principles
- Metformin and Malignant Tumors: Not Over the Hill